Committee Holds Second Hearing on Trump Administration’s Response to the Drug Crisis
Washington, D.C. (May 7, 2019)—On Thursday, May 9, 2019, at 11:00 a.m., the Committee on Oversight and Reform will hold a hearing on “The Trump Administration’s Response to the Drug Crisis, Part II.”
WHERE: 2154 Rayburn House Office Building
WHEN: Thursday, May 9, 2019
TIME: 11:00 a.m.
A livestream will broadcast here.
For two years, the Trump Administration had no drug control strategy—even though the Administration was required by law to issue one in both 2017 and 2018.
On March 7, 2019, the Committee convened a hearing to examine the National Drug Control Strategy finally issued in January 2019 by the Office of National Drug Control Policy (ONDCP). Triana McNeil, the Acting Director of Strategic Issues with the Government Accountability Office (GAO), testified that the drug strategy issued by ONDCP in January does not comply with applicable legal requirements.
GAO testified that “without effective long-term plans, such as a national strategy, that clearly articulate goals and objectives and without specific measures to track performance, federal agencies cannot fully assess whether taxpayer dollars are invested in ways that will achieve desired outcomes.”
ONDCP Director Carroll agreed to provide supplemental documents that meet legal requirements within 60 days. He also agreed to provide the documents GAO requested as part of its ongoing audit of ONDCP’s drug control efforts, and to allow GAO to conduct interviews with agency staff.
According to the Centers for Disease Control and Prevention, “In 2017, there were 70,237 drug overdose deaths in the United States.” This is the highest rate of drug overdose deaths ever observed in the United States.
The Honorable James W. Carroll, Jr.
Office of National Drug Control Policy
Acting Director, Strategic Issues
Government Accountability Office
Karyl Thomas Rattay, M.D., M.S.
Delaware Division of Public Health